Join Growin Stock Community!
Back to NKTR.US Analysis
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

revenue-chart

NKTR Revenue

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

Nektar therapeutics (NKTR) 2025Q3 financial report shows revenue of 11.79M USD, with a YoY growth rate of -51.13%. This clearly indicates that Nektar therapeutics (NKTR) is facing severe revenue challenges and a significant deterioration. To better understand the business situation, investors are advised to look beyond the revenue YoY, and closely examine trends in net profit, operating profit, and gross margin. In addition, leveraging third-party data such as Growin AI Value Analysis will provide a more comprehensive assessment of the operational pressure and potential financial risks faced by Nektar therapeutics (NKTR).